Israel Englander Cellectar Biosciences, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$11.8 - $18.2 $2.91 Million - $4.49 Million	-246,485 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.2 - $25.0 $3.47 Million - $5.71 Million	228,218 Added 1249.35%	246,485 $397,000
Q4 2020 Feb 16, 2021	BUY	$11.2 - $27.7 $204,590 - $505,995	18,267 New	18,267 $38,000
Q3 2020 Nov 16, 2020	SELL	$10.6 - $16.6 $148,760 - $232,964	-14,034 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.3 - $17.3 $144,550 - $242,788	14,034 New	14,034 $18,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.